KR20150023396A - 특정 타겟군의 알콜 섭취량을 줄이기 위한 날메펜 - Google Patents

특정 타겟군의 알콜 섭취량을 줄이기 위한 날메펜 Download PDF

Info

Publication number
KR20150023396A
KR20150023396A KR1020147035322A KR20147035322A KR20150023396A KR 20150023396 A KR20150023396 A KR 20150023396A KR 1020147035322 A KR1020147035322 A KR 1020147035322A KR 20147035322 A KR20147035322 A KR 20147035322A KR 20150023396 A KR20150023396 A KR 20150023396A
Authority
KR
South Korea
Prior art keywords
patient
alcohol
day
drl
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020147035322A
Other languages
English (en)
Korean (ko)
Inventor
라르스 토룹
아프사네 압바리키
안나 블라드스트룀
크리스티네 페르손
디디에 물리앙
페르 쇠렌센
토마스 욘 옌센
예테 부크 외스테르가르드
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150023396(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20150023396A publication Critical patent/KR20150023396A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
KR1020147035322A 2012-06-27 2013-06-27 특정 타겟군의 알콜 섭취량을 줄이기 위한 날메펜 Abandoned KR20150023396A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US61/664,804 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US61/721,539 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US61/736,740 2012-12-13
US201361788810P 2013-03-15 2013-03-15
US61/788,810 2013-03-15
PCT/EP2013/063461 WO2014001427A1 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Publications (1)

Publication Number Publication Date
KR20150023396A true KR20150023396A (ko) 2015-03-05

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035322A Abandoned KR20150023396A (ko) 2012-06-27 2013-06-27 특정 타겟군의 알콜 섭취량을 줄이기 위한 날메펜

Country Status (35)

Country Link
US (4) US20140005217A1 (https=)
EP (5) EP2866808B1 (https=)
JP (3) JP6258933B2 (https=)
KR (1) KR20150023396A (https=)
CN (1) CN104411313A (https=)
AU (1) AU2013283281B2 (https=)
BR (1) BR112014032555A2 (https=)
CA (1) CA2874703C (https=)
CL (1) CL2014003484A1 (https=)
CO (1) CO7160087A2 (https=)
CY (3) CY1118579T1 (https=)
DK (3) DK3138564T3 (https=)
EA (1) EA029908B1 (https=)
ES (4) ES2663532T3 (https=)
FI (1) FI3345604T3 (https=)
HK (1) HK1255683A1 (https=)
HR (4) HRP20161717T1 (https=)
HU (4) HUE036272T2 (https=)
IL (1) IL236035B (https=)
LT (3) LT2866808T (https=)
ME (2) ME02587B (https=)
MX (1) MX371373B (https=)
MY (1) MY166914A (https=)
NZ (1) NZ702191A (https=)
PH (1) PH12014502798A1 (https=)
PL (4) PL4223296T3 (https=)
PT (3) PT2866808T (https=)
RS (2) RS55456B1 (https=)
RU (1) RU2665373C2 (https=)
SG (1) SG11201408704WA (https=)
SI (3) SI3138564T1 (https=)
SM (3) SMT201600471T1 (https=)
UA (1) UA114199C2 (https=)
WO (1) WO2014001427A1 (https=)
ZA (1) ZA201409525B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
EP3134090B1 (en) 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
ES2564006T3 (es) 2009-05-25 2016-03-17 H. Lundbeck A/S Preparación de hidrocloruro de nalmefeno a partir de naltrexona
SMT201700177T1 (it) 2010-11-05 2017-05-08 H Lundbeck As Procedimento per la fabbricazione di naltrexone
WO2012134410A1 (en) 2011-03-31 2012-10-04 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Compositions of opioid antagonists and their use for treating scleroderma
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
MX2014015488A (es) 2015-03-06
HRP20230762T1 (hr) 2023-10-13
ME02587B (me) 2017-06-20
SG11201408704WA (en) 2015-01-29
PL3345604T3 (pl) 2023-08-28
CY1126140T1 (el) 2023-11-15
PL4223296T3 (pl) 2025-04-14
WO2014001427A1 (en) 2014-01-03
RS57046B1 (sr) 2018-05-31
EP2866808A1 (en) 2015-05-06
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
CY1118579T1 (el) 2017-07-12
US20140005217A1 (en) 2014-01-02
JP6857684B2 (ja) 2021-04-14
LT3138564T (lt) 2018-04-10
EP4223296A2 (en) 2023-08-09
EP3138564A1 (en) 2017-03-08
EP3345604A1 (en) 2018-07-11
IL236035B (en) 2018-12-31
MX371373B (es) 2020-01-28
US10034874B2 (en) 2018-07-31
HRP20180363T1 (hr) 2018-04-20
PL3138564T3 (pl) 2018-06-29
AU2013283281B2 (en) 2017-04-20
EP3138564B1 (en) 2018-01-31
JP2015521647A (ja) 2015-07-30
HUE031110T2 (en) 2017-06-28
LT3345604T (lt) 2023-08-10
JP6258933B2 (ja) 2018-01-10
HUE036272T2 (hu) 2018-06-28
US20140005216A1 (en) 2014-01-02
ES2663532T3 (es) 2018-04-13
SMT201600471B (it) 2017-03-08
US20180028526A1 (en) 2018-02-01
HK1208185A1 (en) 2016-02-26
CO7160087A2 (es) 2015-01-15
CY1120097T1 (el) 2018-12-12
EP3345604B1 (en) 2023-06-07
CN104411313A (zh) 2015-03-11
FI3345604T3 (fi) 2023-07-28
CA2874703A1 (en) 2014-01-03
EA029908B1 (ru) 2018-05-31
HK1255683A1 (en) 2019-08-23
HUE063313T2 (hu) 2024-01-28
ES3014068T3 (en) 2025-04-16
CL2014003484A1 (es) 2015-02-27
DK3138564T3 (en) 2018-03-26
DK3345604T3 (da) 2023-07-24
MY166914A (en) 2018-07-24
EP4541421A2 (en) 2025-04-23
ZA201409525B (en) 2016-08-31
NZ702191A (en) 2017-06-30
SI3345604T1 (sl) 2023-08-31
PL2866808T3 (pl) 2017-04-28
SMT201800164T1 (it) 2018-07-17
HUE070621T2 (hu) 2025-06-28
ES2609122T3 (es) 2017-04-18
CA2874703C (en) 2022-08-23
LT2866808T (lt) 2017-01-10
IL236035A0 (en) 2015-01-29
HRP20161717T1 (hr) 2017-02-10
UA114199C2 (uk) 2017-05-10
JP2018039810A (ja) 2018-03-15
HRP20250329T1 (hr) 2025-05-09
AU2013283281A1 (en) 2014-12-11
DK2866808T3 (en) 2017-01-16
EP4541421A3 (en) 2025-06-18
ES2950492T3 (es) 2023-10-10
RU2014151156A (ru) 2016-08-20
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
EA201492152A1 (ru) 2015-11-30
SMT201600471T1 (it) 2017-03-08
SI3138564T1 (en) 2018-04-30
PT3138564T (pt) 2018-04-03
PT2866808T (pt) 2017-01-03
EP4223296B1 (en) 2025-01-29
JP2019163275A (ja) 2019-09-26
US9642849B2 (en) 2017-05-09
HRP20230762T8 (hr) 2024-01-05
PT3345604T (pt) 2023-07-17
EP2866808B1 (en) 2016-11-02
EP4223296A3 (en) 2023-09-27
RS55456B1 (sr) 2017-04-28
BR112014032555A2 (pt) 2017-06-27
EP4223296C0 (en) 2025-01-29
ME03030B (me) 2018-10-20

Similar Documents

Publication Publication Date Title
JP6857684B2 (ja) 特定の標的集団におけるアルコール消費を低減するためのナルメフェン
ES2337622T3 (es) Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos.
HK1229720A1 (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1229720B (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1208185B (en) Nalmefene for reduction of alcohol consumption in specific target populations
CN115989031A (zh) 用于抑制透析转化或肾死亡的药剂
WO2020094591A1 (en) Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
US20160058753A1 (en) Nalmefene for Treatment of Patients with Mood Disorder
WO2014170353A1 (en) Nalmefene for treatment of patients with sleep disorder

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180614

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20180614

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180716

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190325

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee